medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 2

<< Back Next >>

Medicina & Laboratorio 2021; 25 (2)

Hemolytic uremic syndrome in an older adult woman: case report and literature review

Moya-Acuña DM, Rosero-Arellano C

Language: Spanish
References: 27
Page: 536-546
PDF size: 115.25 Kb.


ABSTRACT

The classic or typical hemolytic uremic syndrome (HUS) in adults is a rare disease. Few reports are found in the literature, and it has mainly been documented in the pediatric population. This condition is a form of thrombotic microangiopathy (TMA), which characteristically compromises the kidneys. It is mainly caused by infection with Shiga toxin-producing Escherichia coli (STEC), specifically the O157:H7 serotype. In Colombia there are no reports on this condition in adults, and may be due in part to difficulties in its diagnosis, as there is not easy access to some of the tests that guide towards this condition and confirm the diagnosis. The case of an elderly Colombian woman is reported, who presented diarrhea and hematochezia, and subsequently developed severe thrombocytopenia and acute kidney injury, with evidence of echinocytes and schistocytes in peripheral blood smears, which led to suspect TMA. A gastrointestinal FilmArray™ was ordered, which was positive for STEC, thus confirming the diagnosis of a typical HUS. A brief literature review is also presented, which covers general concepts of a condition that requires an early and accurate diagnosis in order to provide an effective and timely treatment.


REFERENCES

  1. Arnold DM, Patriquin CJ, Nazy I. Thromboticmicroangiopathies: a general approachto diagnosis and management. CMAJ 2017;189:153-159. https://doi.org/10.1503/cmaj.160142.

  2. Cody EM, Dixon BP. Hemolytic uremic syndrome.Pediatr Clin North Am 2019;66:235-246.https://doi.org/10.1016/j.pcl.2018.09.011.

  3. Pandey Y, Atwal D, Sasapu A. Diarrheaassociatedhemolytic uremic syndrome inadults: Two case reports and review of the literature.Cureus 2019;11:e4435. https://doi.org/10.7759/cureus.4435.

  4. Petruzziello-Pellegrini TN, Moslemi-NaeiniM, Marsden PA. New insights into Shiga toxinmediatedendothelial dysfunction in hemolyticuremic syndrome. Virulence 2013;4:556-563.https://doi.org/10.4161/viru.26143.

  5. Piralla A, Lunghi G, Ardissino G, Girello A,Premoli M, Bava E, et al. FilmArray™ GI panelperformance for the diagnosis of acute gastroenteritis or hemorragic diarrhea. BMC microbiology2017;17:111. https://doi.org/10.1186/s12866-017-1018-2.

  6. Palacios-Cuesta A, Ordóñez-Sáez O. Cap.15.3. Síndrome hemolítico urémico. In: MontejoJ, García de Lorenzo A, Marco P, Ortiz C, eds.Manual de Medicina Intensiva. 5a ed. Amsterdam,Países Bajos: Elsevier; 2017.

  7. Nathanson S, Kwon T, Elmaleh M, Charbit M,Launay EA, Harambat J, et al. Acute neurologicalinvolvement in diarrhea-associated hemolyticuremic syndrome. Clin J Am Soc Nephrol2010;5:1218-1228. https://doi.org/10.2215/cjn.08921209.

  8. McCollough M, Rose E. Genitourinary andrenal tract disorders. In: Walls R, HockbergerR, Gausche-Hill M, eds. Rosen’s EmergencyMedicine: Concepts and Clinical Practice. Amsterdam,Países Bajos: Elsevier; 2018. p. 2163-2181. https://www.clinicalkey.es/#!/content/3-s2.0-B9780323354790001732.

  9. Manoharon A, Schelling JR, Diamond M,Chung-Park M, Madaio M, Sedor JR. Chapter82 - Immune and inflammatory glomerular diseases.In: Alpern RJ, Moe OW, Caplan M, eds.Seldin and Giebisch's The Kidney. 5th ed. Massachusetts,Estados Unidos: Academic Press;2013. p. 2763-2816. https://doi.org/10.1016/B978-0-12-381462-3.00082-3.

  10. Ko H, Maymani H, Rojas-Hernandez C. Hemolyticuremic syndrome associated withEscherichia coli O157:H7 infection in olderadults: a case report and review of the literature.J Med Case Rep 2016;10:175. https://doi.org/10.1186/s13256-016-0970-z.

  11. Kavanagh D, Raman S, Sheerin NS. Managementof hemolytic uremic syndrome. F1000PrimeRep 2014;6:119. https://doi.org/10.12703/P6-119.

  12. Keir LS. Shiga toxin associated hemolytic uremicsyndrome. Hematol Oncol Clin North Am2015;29:525-539. https://doi.org/10.1016/j.hoc.2015.01.007.

  13. Bruyand M, Mariani-Kurkdjian P, Gouali M,de Valk H, King LA, Le Hello S, et al. Hemolyticuremic syndrome due to Shiga toxin-producingEscherichia coli infection. Med Mal Infect2018;48:167-174. https://doi.org/10.1016/j.medmal.2017.09.012.

  14. Bowen EE, Coward RJ. Advances in our understandingof the pathogenesis of hemolyticuremic syndromes. Am J Physiol Renal Physiol2018;314:454-461. https://doi.org/10.1152/ajprenal.00376.2017.

  15. Domínguez-Ramírez GA, Blanco-Pertuz PM,Herrera-Rueda GA. Síndrome hemolítico urémicoatípico (SHUa): A propósito de un caso demanejo satisfactorio con eculizumab. Acta MedColomb 2019;44. https://doi.org/10.36104/amc.2019.1301.

  16. Universidad Nacional de Colombia. SHU,una enfermedad con 15 casos registrados enColombia. Bogotá, Colombia: Agencia de Noticiasde la Universidad Nacional de Colombia;2013. Acceso 13 de junio de 2020. Disponibleen http://agenciadenoticias.unal.edu.co/detalle/article/shu-una-enfermedad-con-15-casosregistrados-en-colombia.html.

  17. Fakhouri F, Zuber J, Frémeaux-Bacchi V, LoiratC. Haemolytic uraemic syndrome. Lancet2017;390:681-696. https://doi.org/10.1016/s0140-6736(17)30062-4.

  18. Joseph A, Cointe A, Mariani Kurkdjian P,Rafat C, Hertig A. Shiga toxin-associated hemolyticuremic syndrome: A narrative review.Toxins 2020;12:67. https://doi.org/10.3390/toxins12020067.

  19. Obrig TG, Karpman D. Shiga toxin pathogenesis:kidney complications and renal failure.Curr Top Microbiol Immunol 2012;357:105-136.https://doi.org/10.1007/82_2011_172.

  20. Scully M, Hunt BJ, Benjamin S, Liesner R, RoseP, Peyvandi F, et al. Guidelines on the diagnosisand management of thrombotic thrombocytopenicpurpura and other thrombotic microangiopathies.Br J Haematol 2012;158:323-335. https://doi.org/10.1111/j.1365-2141.2012.09167.x.

  21. Masias C, Cataland SR. The role of ADAMTS13testing in the diagnosis and management ofthrombotic microangiopathies and thrombosis.Blood 2018;132:903-910. https://doi.org/10.1182/blood-2018-02-791533.

  22. Morales-Montoya A. Púrpura trombocitopénicatrombótica. Med Int Mex 2019;35:906-911.

  23. Joseph A, Rafat C, Zafrani L, Mariani-KurkdjianP, Veyradier A, Hertig A, et al. Early differentiationof Shiga toxin-associated hemolyticuremic syndrome in critically ill adultswith thrombotic microangiopathy syndromes.Crit Care Med 2018;46:904-911. https://doi.org/10.1097/ccm.0000000000003292.

  24. Romero S, Sempere A, Gómez-Seguí I, RománE, Moret A, Jannone R, et al. Practiceguidelines for the emergency treatment ofthrombotic microangiopathy. Med Clin (Barc)2018;151:123. https://doi.org/10.1016/j.medcli.2018.01.013.

  25. Katsuno T, Ito Y, Kagami S, Kitamura H,Maruyama S, Shimizu A, et al. A nationwidecross-sectional analysis of thrombotic microangiopathyin the Japan Renal Biopsy Registry(J-RBR). Clin Exp Nephrol 2020;24:789-797.https://doi.org/10.1007/s10157-020-01896-7.

  26. Mühlen S, Dersch P. Treatment strategies for infectionswith shiga toxin-producing Escherichiacoli. Front Cell Infect Microbiol 2020;10:169.https://doi.org/10.3389/fcimb.2020.00169.

  27. Kakoullis L, Papachristodoulou E, Chra P, PanosG. Shiga toxin-induced haemolytic uraemicsyndrome and the role of antibiotics: a globaloverview. J Infect 2019;79:75-94. https://doi.org/10.1016/j.jinf.2019.05.018.




2020     |     www.medigraphic.com